HPV Prevalence 4.9 Percent in Tonsil Tissue of Healthy Adults

Share this content:
HPV Prevalence 4.9 Percent in Tonsil Tissue of Healthy Adults
HPV Prevalence 4.9 Percent in Tonsil Tissue of Healthy Adults

WEDNESDAY, Feb. 7, 2018 (HealthDay News) -- The prevalence of human papillomavirus (HPV) and of high-risk HPV type 16 or 18 is 4.9 and 3.9 percent, respectively, in the tonsil tissue of healthy adults, according to a study published online Jan. 25 in JAMA Otolaryngology-Head & Neck Surgery.

Katherine K.S. Rieth, M.D., from the University of Rochester Medical Center in New York, and colleagues conducted a retrospective cross-sectional study using samples obtained from tonsils that were archived following elective nononcologic tonsillectomy from 2012 to 2015. Formalin-fixed paraffin embedded samples of tumor-free tonsil tissue from 102 adults aged 20 to 39 years were included.

The researchers found that the overall prevalence of HPV was 4.9 percent and of high-risk type 16 or 18 HPV was 3.9 percent in tonsils from 102 otherwise healthy adults. In situ hybridization colocalized HPV virus to the biofilm of the tonsillar crypts in this sample population.

"Biofilm is present in the tonsillar crypts in a considerable proportion of tonsil tissues and may be reproducibly identified. Human papillomavirus is demonstrated to colocalize to the crypt biofilm," the authors write. "This has important implications with respect to the determination of HPV prevalence rates in the oropharynx. It may also play a role in the pathogenesis of HPV-related oropharyngeal carcinoma."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »